Trial Profile
Mirabegron,beta-3 adrenoceptor agonist, Evaluate on efficacy, tolerability and QOL,in female overactive bladder with nocturia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 May 2016
Price :
$35
*
At a glance
- Drugs Mirabegron (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Acronyms METEOR
- 25 Sep 2015 Status changed from recruiting to completed, as per University Hospital Medical Information Network - Japan record.
- 17 Jan 2014 New trial record